It’s time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
NEW YORK, Nov 22- U.S. stocks edged higher on Friday in the absence of economic data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials closed above 16,000 for the first time.
NEW YORK, Nov 22- U.S. stocks were little changed on Friday amid a dearth of data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials broke 16,000 for the first time.
*Time Warner Cable up as Charter nears bank deal for bid. NEW YORK, Nov 22- U.S. stocks were set to tick up at the open on Friday after the Dow industrials closed above 16,000 for the first time, amid a dearth of data and ahead of a holiday-shortened week in the United States.
Nov 22- Ariad Pharmaceuticals Inc said European regulators recommended the approval of its leukemia drug, Iclusig, whose U.S. sale has been suspended due to safety concerns, sending the company's shares up 24 percent in premarket trading.
Nov 1- Ariad Pharmaceuticals Inc adopted a shareholder rights plan to protect its tax credits, a day after sales of its flagship drug Iclusig were suspended due to safety concerns following an investigation by the U.S. health regulator.
*Ariad says working with FDA to find a way to bring drug back. WASHINGTON, Oct 31- Ariad Pharmaceuticals Inc has suspended sales of its leukemia drug Iclusig after an investigation by the U.S. Food and Drug Administration found that a significant number of patients developed life-threatening blood clots or narrowing of the veins.
Ariad's troubles started earlier this month when the FDA placed a partial hold on a late-stage trial after a number of patients taking Iclusig experienced blood clots and heart damage. The decision to suspend sales was taken in response to a request by the FDA, Ariad said in a statement on Thursday.
Oct 31- Ariad Pharmaceuticals Inc said it was suspending the sale of its blood cancer drug, Iclusig, barely two weeks after it stopped a late-stage trial of the drug due to safety concerns.
"People are afraid that they're going to have to take the drug off the market," Summer Street Research analyst Carol Werther told Reuters. Ariad's Chief Scientific Officer, Tim Clackson, said he did not expect the drug to be withdrawn, but that it was likely an FDA advisory panel would evaluate the risks and benefits of the drug next year.
The company said on Friday it had come to an agreement with the FDA that the trial should be terminated. The FDA said last week it was investigating a number of reports of serious and life-threatening adverse events in patients taking the drug.
Oct 18- Ariad Pharmaceuticals Inc said it would discontinue a late-stage trial of its blood cancer drug, barely two weeks after the U.S. Food and Drug Administration placed a partial hold on enrollment for all trials testing the drug.
The notice comes after Ariad disclosed on Wednesday that the FDA asked the company to stop enrolling patients in clinical trials of Iclusig. Iclusig was approved by the FDA in December 2012 to treat adults with two rare types of blood cancers- chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
*Wall St looking past Washington gridlock at more gains-poll. NEW YORK, Oct 9- U.S. stocks fell on Wednesday, with the Nasdaq composite index down 1 percent, as investors sold the year's biggest winning shares, including major tech companies. On Wednesday, Amazon.com and Facebook were the biggest drags on the Nasdaq 100. Netflix was down 4.7 percent to $288.36.
NEW YORK, Oct 9- U.S. stocks were little changed on Wednesday, as expectations that Janet Yellen will be tapped as the next head of the U.S. Federal Reserve were tempered by the stalemated fiscal negotiations in Washington.
*Alcoa rises, Yum falls after earnings. NEW YORK, Oct 9- U.S. stocks were little changed on Wednesday, as expectations that Janet Yellen will be tapped as the next chairman of the U.S. Federal Reserve were tempered by a continued stalemate in fiscal negotiations in Washington.
*Alcoa rises, Yum falls after earnings. NEW YORK, Oct 9- U.S. stocks were set for a modestly higher open on Wednesday, putting the S&P 500 on track to rebound from a big drop a day earlier, on expectations Janet Yellen will be tapped as the next chairman of the U.S.
Some of the names on the move ahead of the open.
NEW YORK, July 1- Onyx Pharmaceuticals Inc, whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer Inc and Novartis AG, two people familiar with the matter said on Monday.
Three tech laggards could have strong upside, Zack Safran of Ivy Science & Technology Fund says.
TheStreet.com offers up 13 biotech predictions for 2013.